{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T21:01:18Z","timestamp":1784667678122,"version":"3.55.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ekir.2026.106374","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T17:01:42Z","timestamp":1771866102000},"page":"106374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cystatin C Confirms the Canagliflozin eGFR Slope Benefit in CANPIONE"],"prefix":"10.1016","volume":"11","author":[{"given":"Satoshi","family":"Miyamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiddo J.L.","family":"Heerspink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dick","family":"de Zeeuw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Hatanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Murao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Hida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Akai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munehiro","family":"Kitada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Sugano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomokazu","family":"Nunoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motofumi","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuaki","family":"Nakatou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiji","family":"Kawanami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Miyatake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Kuramoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Shikata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2026.106374_bib1","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1111\/dom.14731","article-title":"Rationale, design and baseline characteristics of the effect of canagliflozin in patients with type 2 diabetes and microalbuminuria in the Japanese population: the CANPIONE study","volume":"24","author":"Miyamoto","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ekir.2026.106374_bib2","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.kint.2024.08.019","article-title":"A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope","volume":"106","author":"Miyamoto","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106374_bib3","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMra054415","article-title":"Assessing kidney function--measured and estimated glomerular filtration rate","volume":"354","author":"Stevens","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106374_bib4","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/j.1523-1755.2004.00517.x","article-title":"Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement","volume":"65","author":"Knight","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106374_bib5","doi-asserted-by":"crossref","first-page":"874","DOI":"10.2215\/CJN.00600206","article-title":"Surrogate end points for clinical trials of kidney disease progression","volume":"1","author":"Stevens","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106374_bib6","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1111\/dom.14508","article-title":"Effects of 1-year treatment with canagliflozin on body composition and total body water in patients with type 2 diabetes","volume":"23","author":"Matsuba","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ekir.2026.106374_bib7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12933-019-0852-y","article-title":"Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy","volume":"18","author":"Schork","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ekir.2026.106374_bib8","article-title":"Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ekir.2026.106374_bib9","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1681\/ASN.2009020171","article-title":"Measured GFR as a confirmatory test for estimated GFR","volume":"20","author":"Stevens","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106374_bib10","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.2337\/dc23-0261","article-title":"Effects of tirzepatide versus insulin glargine on cystatin C-based kidney function: a SURPASS-4 post hoc analysis","volume":"46","author":"Heerspink","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2026.106374_bib11","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/ki.2008.638","article-title":"Factors other than glomerular filtration rate affect serum cystatin C levels","volume":"75","author":"Stevens","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106374_bib12","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2026.106374_bib13","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1053\/j.ajkd.2012.07.007","article-title":"Collaborators Developing the Japanese Equation for Estimated GFR. Collaborators developing the Japanese equation for estimated GFR. GFR estimation using standardized serum cystatin C in Japan","volume":"61","author":"Horio","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2026.106374_bib14","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1681\/ASN.0000000000000037","article-title":"A novel creatinine muscle index based on creatinine filtration: associations with frailty and mortality","volume":"34","author":"Ballew","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106374_bib15","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.kint.2024.06.007","article-title":"Clinical trial designs to assess treatment effects on glomerular filtration rate decline","volume":"106","author":"Heerspink","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106374_bib16","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.kint.2024.07.023","article-title":"The renal function trajectory in clinical trial design: challenges and opportunities","volume":"106","author":"Rosansky","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106374_bib17","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.cmet.2021.02.016","article-title":"A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors","volume":"33","author":"Sen","year":"2021","journal-title":"Cell Metab"},{"key":"10.1016\/j.ekir.2026.106374_bib18","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.2019010007","article-title":"GFR slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials","volume":"30","author":"Inker","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106374_bib19","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1038\/s41591-023-02418-0","article-title":"A meta-analysis of GFR slope as a surrogate endpoint for kidney failure","volume":"29","author":"Inker","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.ekir.2026.106374_bib20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2215\/CJN.0000000630","article-title":"Improving patient selection in clinical trials: should we start using the pretrial eGFR decline as risk enrichment criterion?","volume":"20","author":"Jongs","year":"2025","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926026057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926026057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T20:04:43Z","timestamp":1784664283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024926026057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2468024926026057"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2026.106374","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cystatin C Confirms the Canagliflozin eGFR Slope Benefit in CANPIONE","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2026.106374","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106374"}}